Question · Q3 2025
Robert Justin Marcus inquired about the dynamics of Abbott's diabetes business, specifically U.S. versus OUS performance, market development, and the potential impact of the ketone sensor and CMS coverage for non-intensive Type 2 diabetes. He also asked for feedback on the Volt PFA catheter in Europe and its expected U.S. ramp.
Answer
Chairman and CEO Robert Ford clarified that U.S. diabetes growth was 19% in Q3, with year-to-date growth at 25%, attributing earlier higher growth to shelf restocking. He anticipates strong U.S. growth in 2026 driven by the new dual analyte sensor and continued basal segment penetration, noting potential CMS coverage for Type 2 non-insulin users. For EP, he highlighted accelerating growth, positive European feedback on Volt PFA catheter's efficacy, safety, and N-Site integration, expecting a U.S. launch around mid-2026 and improved EP performance.